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Purpose—To recommend principles for including drug-drug interactions (DDIs) in clinical 
decision support.
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Methods—A conference series was conducted to improve clinical decision support (CDS) for 
DDIs. The Content Workgroup met monthly by webinar from January 2013 to February 2014, 
with two in-person meetings to reach consensus. The workgroup consisted of 20 experts in 
pharmacology, drug information, and CDS from academia, government agencies, health 
information (IT) vendors, and healthcare organizations. Workgroup members addressed four key 
questions: (1) What process should be used to develop and maintain a standard set of DDIs?; (2) 
What information should be included in a knowledgebase of standard DDIs?; (3) Can/should a list 
of contraindicated drug pairs be established?; and (4) How can DDI alerts be more intelligently 
filtered?
Results—To develop and maintain a standard set of DDIs for CDS in the United States, we 
recommend a transparent, systematic, and evidence-driven process with graded recommendations 
by a consensus panel of experts and oversight by a national organization. We outline key DDI 
information needed to help guide clinician decision-making. We recommend judicious 
classification of DDIs as contraindicated, as only a small set of drug combinations are truly 
contraindicated. Finally, we recommend more research to identify methods to safely reduce 
repetitive and less relevant alerts.
Conclusion—A systematic ongoing process is necessary to select DDIs for alerting clinicians. 
We anticipate that our recommendations can lead to consistent and clinically relevant content for 
interruptive DDIs, and thus reduce alert fatigue and improve patient safety.
BACKGROUND AND SIGNIFICANCE
Exposure to potential drug-drug interactions (DDIs) can cause preventable patient harm and 
requires proper management.1 Many electronic prescribing and medication information 
systems include interruptive alerts and non-interruptive information as forms of clinical 
decision support (CDS) to warn clinicians that potential DDIs exists based on a patient’s 
medication history.2,3 DDI alerts most commonly occur during the prescriber medication 
order entry or the pharmacist dispensing/verification process. The Centers for Medicare & 
Medicaid Services (CMS) included DDI screening in the agency’s guidelines for achieving 
meaningful use of electronic health records (i.e., CMS Meaningful Use Core Measure 2).4 
Today, every pharmacy and increasing numbers of physician offices and healthcare 
organizations in the United States employ some form of health information technology (IT) 
that includes DDI alerts.5
The content of the vast majority of DDI decision support systems in the United States is 
created, maintained, and sold by drug knowledgebase vendors that use their own approach 
for evaluating and classifying the clinical importance of DDIs.6 Studies have demonstrated 
substantial variability in DDI alerting performance across electronic prescribing and 
pharmacy software systems.7–14 Ubiquitous and low clinical relevance alerts have 
contributed to considerable clinician frustration and dissatisfaction15–17 and reported 
override rates for DDI alerts consistently exceed 90%.18–20 Commentators have stated that 
“the current DDI alert system is broken.”14 A systematic and transparent process with 
ongoing governance and infrastructure is imperative to improve the clinical relevance and 
consistency of DDI alerts.
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To address the aforementioned issues we conducted a conference series to develop specific 
recommendations to improve the quality of CDS alerts for DDIs. These activities were 
supported in part by a conference grant from the Agency for Healthcare Research and 
Quality and donations from health IT vendors. Recommendations by other workgroups were 
published separately.21,22 This paper describes recommendations by a workgroup to create a 
process to establish a standard set of DDIs for CDS.
MATERIALS AND METHODS
As part of a larger conference series to improve the quality of CDS for DDIs, 20 individuals 
with expertise in DDIs, clinical pharmacology, CDS, and establishing healthcare quality 
initiatives were invited and agreed to participate. The workgroup’s primary goal was to 
recommend principles and processes for including DDIs in drug safety alerts that would 
ultimately guide the development and maintenance of a standard set of DDIs for CDS. 
Members represented diverse backgrounds such as academia, drug knowledgebase vendors, 
drug information compendia, clinicians, professional societies, and the Office of the 
National Coordinator for Health IT (ONC); and the Food and Drug Administration.
The workgroup met monthly by webinar from January 2013 to February 2014, with live 
meetings held in Washington DC (May 2013) and Phoenix, Arizona (September 2013). 
Recommendations were developed by consensus after completing a literature review on 
methods and best practices for establishing consensus in decision-making. Draft questions 
were proposed by two members and the entire group modified and addressed the following 
key questions:
1. What process should be used to develop and maintain a standard set of 
DDIs?
2. What information should be included in a knowledgebase of standard 
DDIs?
3. Can/should a list of contraindicated drug pairs be established?
4. How can DDI alerts be more intelligently filtered?
The focus of this project was drug-drug interactions. We recognize that many other types of 
interactions (e.g. drug-food, drug-herbal, drug-disease) exist but were considered outside the 
scope of this project. Many of these interactions share a number of characteristics that are 
similar, but we did not attempt to address all of the issues across all types of interactions. 
Recommendations in this paper may be relevant to these other interactions.
RESULTS
Key Question 1: What process should be used to develop and maintain a standard set of 
DDIs?
A key component of improving the relevance of DDIs is identifying DDIs with clinical 
consequences warranting interruption of the ordering process. Phansalkar et al. identified an 
initial set of high priority DDIs through an ONC task order that could be used as a minimum 
standard for electronic health record systems23 and a set of DDIs that should be non-
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interruptive in order to reduce alert fatigue.24 Because clinical knowledge changes over time 
and new products are brought to market, an ongoing process is needed with governance and 
infrastructure to ensure that a standard set of DDIs is regularly updated and reflects current 
evidence and newly discovered DDIs. This undertaking is not trivial and requires substantial 
resources.
In light of these issues and ongoing challenges, we recommend forming a national 
consensus panel of experts to create and maintain a standard set of clinically relevant DDIs 
for CDS systems, with oversight by a national organization to ensure that the process is 
transparent, systematic, and evidence-driven (Figure 1). Key elements for developing 
trustworthy clinical recommendations include ensuring that expert panelists consider 
relevant evidence, including relevant stakeholders, providing opportunities for public 
comment, documenting panelist and external reviewer comments and responses, and actively 
managing conflicts of interest.25–28
National Process with Centralized Oversight—We recommend selecting a 
centralized organizer or convener, such as an academic unit or a professional association or 
organization (e.g., American Society of Health-System Pharmacists, American Society for 
Clinical Pharmacology and Therapeutics, American Medical Informatics Association, etc.) 
with full-time staff, to serve as the driving force to convene the panel and disseminate 
information.29,30 The goal should be to maintain the evidence base and decision algorithms 
for the ‘public good’ and, therefore, public funding must support this venture to align and 
promote collaboration among the public and private sectors. We recommend a standard set 
of DDIs for use in CDS should be created and maintained independent of reimbursement 
decisions. This evidence base could be established so that it is accessible as a web service, 
so that it could be utilized by many providers and healthcare systems.
We recommend that a panel of experts be created and include individuals with clinical 
expertise and skills in evaluating DDIs. Because of concerns of being too prescriptive we 
recommend that members of the inaugural panel define the following attributes: the 
appointment process; terms of membership; procedural rules (e.g., voting policies and 
procedures); framework for executing the steps involved in grading recommendations; 
policies for managing potential conflict of interest; and the policies and procedures of a 
comprehensive and transparent DDI selection process (e.g., methods for evidence summary 
and presentation, balloting procedures).
Use of expert advice is particularly important because the types and quality of evidence 
available for DDIs differ substantially from other areas of clinical practice. Furthermore, 
research indicates that expert advice improves the acceptance and value of DDI alerts.15,31 
We recommend including individuals with clinical expertise and skills in evaluating DDIs. 
Furthermore, experts should have a background in clinical pharmacology, pharmacokinetics, 
pharmacoepidemiology, medication safety, clinical experience in relevant clinical 
subspecialties, health information technology, and human factors engineering.
Evidence Synthesis—We recommend a systematic process for assembling DDI 
evidence, similar to approaches used for systematic reviews and practice guideline 
Tilson et al. Page 4
Am J Health Syst Pharm. Author manuscript; available in PMC 2016 October 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
development.32–37 Qualified experts should summarize the evidence and quality assessment 
for presentation to the national expert panel for deliberation. Another workgroup associated 
with this initiative has developed a new evaluation tool - the DRug Interaction eVidence 
Evaluation (DRIVE) instrument—to establish sufficient evidence for DDIs that may require 
clinical management.21 Before widespread use, the instrument should undergo testing and 
validation. That said, the DRIVE instrument or other approaches should be incorporated into 
the process to provide clinicians a clear rating of the overall quality of evidence, with graded 
recommendations for clinical management.34
Grading Recommendations for Risk Management—A major challenge in applying 
this approach to DDIs is defining the hierarchy of graded risk management 
recommendations in such a way that, despite the often-weak nature of DDI evidence, 
confidence can be placed in the recommendations to adequately support them.34,38 It also 
will be important to present the hierarchy of graded risk management recommendations in a 
manner that is comprehensible to a wide range of users.39 The Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) approach has been adapted to DDIs 
and could be further refined for this process.21,32,33,35 Although the graded DDI 
recommendations will be advisory in nature, we expect that the approach used by the 
organizer/convener will promote trust among prescribers and pharmacists so 
recommendations can be confidently applied.
Community Feedback on DDI Recommendations—We recommend that a web-
based process be created and maintained to solicit input concerning classification of DDIs. 
Input from numerous stakeholders, including clinicians, healthcare and quality 
organizations, government agencies, IT vendors, and pharmaceutical companies are strongly 
encouraged. Broad-based feedback is essential for both maintenance and quality 
improvement in managing the knowledgebase.40 It should be easy for prescribers, 
pharmacists, and other clinicians to submit petitions to the panel to add or re-evaluate drug 
combinations (e.g., up- or down-grading classification). Requests to remove or add DDIs 
should be evaluated based on clinical and scientific merits.
Subsequent Evaluation, Re-evaluation, and Updates—Periodic and timely updates 
of the standard set of DDIs are essential.41 We recommend at least annual updates, given the 
dynamic nature of DDI knowledge acquisition, and we defer to the expert panel for 
specifications of the process. We also recommend that the standard set of DDIs be aligned 
with other national initiatives – both public and private (e.g., quality organizations) when 
creating quality metrics for healthcare organization quality assessments, including such 
organizations as the Pharmacy Quality Alliance and the National Quality Forum.
Key Question 2: What information should be included in a knowledgebase of standard 
DDIs
Based in part on recommendations by Floor-Schreudering et al.,34 we formulated a list of 
information to be included, along with the interacting drug pairs, in a standard set of DDIs to 
optimally guide clinicians in mitigating or preventing harm. These include: (1) classification 
of seriousness; (2) clinical consequences; (3) frequency of harm and exposure; (4) 
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modifying factors; (5) interaction mechanism; (6) recommended action (with strength of 
recommendations); and (7) evidence (with quality ratings).
Classification (Seriousness Rating) and Meanings—The classification system for 
DDI must reflect and include an explanation of medical logic so the justification is intuitive 
to the end user (provider/pharmacist).42 Information on the criteria used to classify drug 
pairs should be readily accessible. We recommend that classification terms (e.g., major, 
moderate, minor) be clearly defined, easily recognized, transparent, and simple. Many 
organizations and individuals refer to classification of DDIs by the “severity” of the 
interaction. We prefer the more precise term, “seriousness,” defined as the extent to which 
an adverse reaction can or does cause harm.43 Severity is more ambiguous and describes the 
intensity of an adverse reaction in an individual. For example, a headache may be severe but 
not serious. Seriousness, severity, and selected other terms related to DDIs have defined by 
others.21
The overall classification of an interaction should be driven by the seriousness and frequency 
(when available) of the potential clinical outcome, taking the clinical management 
recommendation(s) and strength of evidence into account. We recommend that decision 
support systems for DDIs use no more than three categories of seriousness. The rationale is 
to simplify and increase the consistency of these classification systems. The highest 
seriousness category should be for interruptive alerts for DDIs requiring clinician action. 
The middle category should be for DDIs requiring some form of clinician notification but 
that do not necessarily need to be an interruptive alert. The lowest category should be for 
clinically inconsequential DDIs that generally should not be included in notification 
systems.24
Clinical Consequences and Frequency—The potential adverse clinical consequences 
for the patient as a result of co-prescribing the interacting drugs should be clearly described. 
For example, simply stating that ciprofloxacin may increase the blood levels of theophylline 
is insufficient. Clinical effects of theophylline toxicity such as nausea, vomiting, 
cardiovascular instability, and seizures should be provided with the decision support 
information. Clinicians can make better therapeutic decisions for specific patients when the 
potential clinical consequences are clearly identified.44
When available, the frequency or incidence of adverse outcomes associated with a specific 
DDI should be stated in numbers (e.g., 1/1000). A verbal scale may be necessary, 
recognizing that numerical values are often unavailable and that estimated frequencies are 
often ranges of measures of central tendency (e.g., means) with wide variability from 
different studies.45 One example is the standard frequency groupings for adverse effects 
used by the European Medicines Agency: very common (≥1/10); common (≥1/100 to 
<1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
(<1/10,000); and not known (cannot be estimated from the available data).46
There are several impediments to identifying frequency estimates, such as underreporting, 
the nature of DDI evidence, and variability in the seriousness of adverse outcomes. Adverse 
reactions resulting from DDIs are likely to be underreported and the majority of clinical 
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evidence is currently derived from pharmacokinetic studies and case reports. 
Epidemiological evidence is infrequently published and, for most DDIs, evidence is 
sufficient to make only rough estimates of the incidence of adverse outcomes. In the near 
term, frequency is unlikely to be a commonly populated field, but clinicians should be 
informed that the rate of adverse events is unknown when not available.34
Modifying (Risk or Mitigating) Factors—The risk of harm associated with a DDI is a 
function of both seriousness and frequency of the event, combined with individual patient 
susceptibility. Risk factors increase patient susceptibility and mitigating factors decrease 
susceptibility. For example, risk factors for hyperkalemia among patients taking angiotensin-
converting enzyme (ACE) inhibitors and potassium-sparing diuretics including renal 
impairment, diabetes, and elevated baseline potassium levels. Providing clinicians with 
information about factors that modify patient susceptibility is essential for assessing the risk 
of patient harm. For most DDIs, however, factors that modify the risk of an adverse outcome 
are often not known. Research shows that providing clinicians with alerts containing patient-
specific risk factors can reduce the risk of injury.47 Known modifying factors (such as 
patients’ genetic information, ethnicity, concomitant diseases, etc.) should be included in 
DDI alerts, and when factors are not known, the lack of information should also be stated.
Interaction Mechanism—We recommend that clinically relevant information regarding 
interaction mechanisms, such as differentiating between pharmacokinetic and 
pharmacodynamics effects, should be included with the standard set of DDIs. This 
information may be useful to assess patient risk and identify reasonable therapeutic 
alternatives.
Recommended Actions in DDIs CDS—Providing a statement of possible harm without 
recommending a corresponding action is generally not an effective way to change clinician 
behavior.48,49 Clinicians may resist an alert when an acceptable alternative is not offered.49 
We strongly recommend that CDS systems should provide actionable recommendations—
that is, guidance on ways to mitigate or avoid the potential for harm, especially when a 
clinician’s workflow is interrupted to display a potentially serious DDI. This could include a 
recommendation to closely monitor the patient while on the combination therapy. When the 
benefits of both medications outweigh the risks, it is critical to convey to the clinician 
strategies to minimize the potential for adverse outcomes, such as specific monitoring (e.g., 
vitals, labs, therapeutic drug monitoring) or dosage adjustments (e.g., 50% dose reduction). 
However, if the seriousness of the interaction dictates that the drugs should not be used 
together, the clinician must be presented with the option to discontinue one or both 
medications. As described previously, clear indications of the strength of the 
recommendations should accompany clinical advice.
Evidence—Providing access to the evidence is a critical component of weighing the risks 
and benefits. Unfortunately, many DDIs are based on limited evidence, such as a few case 
studies and perhaps pharmacokinetic evaluations. We recommend that DDI alerts should 
indicate the quality of evidence (with definitions), summarize the evidence briefly, and 
provide access to references from the primary literature when possible. Beyond the evidence 
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to substantiate the existence of a DDI, evidence ratings should also be provided when 
available for adverse effects, frequency, risk factors, and management strategies. In addition 
to ratings for the quality of evidence, links to primary sources should be accessible through 
the knowledgebase. Another workgroup associated with this project has recommended links 
to primary references through PMID numbers for PubMed or similar systems in other 
abstracting databases.22
Key Question 3: Can/should a list of contraindicated drug pairs be established?
It is important to recognize that there has been inconsistent use of the term “contraindicated” 
in various drug information sources. Contraindicated DDIs are those for which no situations 
have been identified where the benefit of the combination outweighs the risk.3 Using this 
definition, there are no circumstances where an override is an acceptable action for 
contraindicated DDIs. In a review of contraindicated DDI alerts from a commercial 
knowledgebase, Hatton et al. suggested that most “contraindicated” drug pairs were not 
absolute contraindications and could be “downgraded.”14 For example, according to the 
sildenafil product labeling, sildenafil is contraindicated in patients regularly or intermittently 
using organic nitrates.50 As such, many CDS systems produce DDI alerts identifying 
sildenafil and nitrates as contraindicated. However, evidence indicates that sildenafil and 
nitrates can be used intermittently with adequate separation of dosing (e.g., nitroglycerine 
may be considered 24 hours after sildenafil dosing) or with appropriate blood pressure 
monitoring).51,52 Classifying an interaction as “contraindicated” should be done judiciously 
and perhaps infrequently, as only a small set of drug combinations are absolutely 
contraindicated. The Food and Drug Administration is aware of this issue and is making 
steps to limit the use of the term “contraindicated” or inferred contraindication in product 
labeling information. For example, rather than using the term “contraindicated,” the labeling 
of ibrutinib states to “Avoid co-administration with strong or moderate CYP3A inhibitors 
and consider alternative agents with less CYP3A inhibition,” and provides specific 
instructions on how to manage the interaction.53 Many times the contraindication may 
reflect avoidance of simultaneous administration, but this clarification needs to be included 
with the CDS notification. In other situations it may be appropriate to classify co-
administration of two products as contraindicated based on extrapolation from other 
medications with similar pharmacologic properties (e.g., use of a novel antidepressant in 
combination with a monoamine oxidase inhibitor). Furthermore, a separate 
“contraindicated” classification should not be used for DDI alerts.
Key Question 4: How can DDI alerts be more intelligently filtered?
In an effort to reduce alert fatigue, many organizations have implemented local 
customization/revision of alerting rules.42 However, implementation and modification of 
commercially developed CDS may result in unnecessary and/or error-inducing conditions 
that may need to be addressed at the organizational level.54,55 There is lack of evidence on 
what approaches should be used when trying to filter alerts. Consequently, healthcare 
organizations should use an interprofessional committee, including physicians and 
pharmacists, to periodically review frequently overridden alerts and suggest safe and 
effective ways for either suppressing alerts of low value or changing their presentation 
format.56 Individual users should be able to provide feedback to the committee about the 
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system at any point in the care process as part of a continuous improvement process. It is 
unclear whether individual clinicians should be allowed to turn off specific alerts they 
consider uninformative or whether entire classes of alerts could be safely suppressed for 
particular specialists, who may not need the same level of support as generalists.42 An 
alternative approach would be to allow a prescriber to defer or forward an alert to a 
pharmacist for review during order verification when adjusting administration times can 
circumvent the DDI. We considered the question of whether organizations should identify a 
group of “expert” professionals that should be exempt from DDI notifications. However, 
there is no research to support that this approach protects patient safety.57
Keeping in mind the five “rights” for health IT medication safety (right information, right 
person, right CDS format, right channel, right time in workflow),58 there are situations 
where DDI notification is repetitive or irrelevant. For example, in some systems, DDI alerts 
may be generated for refills or continuations of existing medications. Changes in dosing, 
strength, time of administration, and transfer between inpatient units can result in repetitive 
alerts that contribute to alert fatigue. Some experts advocate the ability to suppress alerts at 
the time of renewal of previously tolerated medication combinations for the same 
patient.59,60 Patients with long-term use of certain medications may have demonstrated their 
capacity to tolerate them and suppressing alerts for refills might be an option in some 
circumstances.61 We do not provide recommendations on this issue because of the paucity of 
evidence. We encourage organizations that design or modify CDS rules to evaluate outcomes 
and report to the medical community the effectiveness and safety of such modifications.
Filtering alerts by increasing the specificity of trigger rules may help to decrease irrelevant, 
interruptive messages.62–64 More sophisticated rules need to be developed to enable 
intelligent alerting. Ideally, DDI alerts should be patient-specific, taking into account age, 
gender, genetics, body weight, allergies, drug serum levels, renal function, comorbidity, and 
other mitigating factors.65 Table 1 provides an overview of situations where a particular DDI 
alert may be intelligently ignored in a specific patient. We recognize the challenges posed by 
incorporating mitigating factors into DDI alerts and that there is often insufficient clinical 
evidence to improve patient-specificity for many interactions. As CDS systems become 
more sophisticated, developers are encouraged to take context into account when designing 
alerts. Given the current state of the evidence, we do not support indiscriminately “turning 
off” alerts,55 and recommend that modifications to DDI alerts be done cautiously, with 
careful evaluation to ensure that patient safety is not compromised. Furthermore, suggesting 
strategies to actively monitor for signs of harm for patients on concomitant therapies that 
may result in a DDI should be incorporated into CDS systems.
DISCUSSION
The purpose of this paper is to present recommendations from a national workgroup on 
approaches that should be undertaken to improve CDS for DDIs. We believe that 
implementing these recommendations will provide substantive improvements to current 
systems. Foremost, employing a systematic process with graded recommendations and full 
transparency for a nationally vetted, standard set of clinically relevant DDIs will build trust 
among clinicians and foster collaboration among healthcare organizations and IT 
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vendors.25,26,28,42 The threat of liability often dominates the decision to list a drug pair as a 
DDI, even when evidence or even plausibility is lacking. We believe a systematic process 
will help mitigate liability risk and may reduce alert burden and ultimately improve patient 
safety.29,30 Presently, there is no well-defined, broadly accepted standard for grading the 
quality of a body of evidence for a DDI and for providing strengths of recommendations for 
patient risk management strategies.23,24,29,30,34 In addition, research is needed to develop 
new approaches that will further allow further refinement of DDIs such as consideration of 
patient characteristics when considering if or how to fire a DDI. Filling these unmet needs is 
an important goal to provide widely accepted and consistent DDI alerts.
Creating and maintaining a list of DDIs is a resource-intensive, time-consuming, and 
continuous process, not a one-time activity. The task a central organizer/convener will face 
to create and maintain the proposed knowledgebase and standard set of DDIs is enormous. 
Much oversight will be required to coordinate evidence evaluation and continual updates. 
Decisions should be subject to periodic review along with regular review of underlying 
methods to remain current with evolving scientific knowledge. Support and buy-in (or 
adoption) from the major stakeholders will be essential to the success of the endeavor. To 
minimize issues of bias, we recommend that public funding take the lead in supporting these 
administrative efforts. The standard set of DDIs should be aligned with other national 
initiatives – both public and private (e.g., quality organizations) when creating quality 
metrics for healthcare organizations.
Given the cost and difficulty of securing continued public funding, the primary challenge to 
implementing our recommended process is sustainability. An innovative public-private 
partnership is needed with endorsement and support from all relevant stakeholders, 
including government agencies, professional organizations, drug knowledgebase and 
compendia editors, and healthcare systems. Currently, there is no process in place that brings 
the collective knowledge of DDI experts, including knowledgebase/compendia editors, 
together to reach consensus on those interactions that should be included in warning 
systems. Collaboration and pooling of limited resources will be necessary to maintain a 
current standard set of DDIs to protect patient safety.
Much work is needed to provide evidence-based recommendations for other changes to 
implementing DDI alerts. Table 2 lists areas of future research that would support 
modifications to DDI alerting systems. Although filtering of alerts by provider type is often 
suggested in the literature, we recommend that modifications to systems be evaluated prior 
to implementation to ensure that patient safety is not compromised.
CONCLUSION
Our purpose was to improve the content of DDI alerts. To this end, our primary 
recommendation is to establish an expert panel with a centralized organizer/convener to 
develop and maintain a standard set of DDIs for CDS in the United States. The process 
should be evidence-driven, transparent, and systematic, with feedback from multiple 
stakeholders for continuous improvement. The scope of the expert panel’s work should be 
carefully managed to assure the process is sustainable. Support for research to improve DDI 
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alerting in the future is also needed. We anticipate that our recommendations can lead to 
consistent and clinically relevant content for interruptive DDI, and thus reduce alert fatigue 
and improve patient safety.
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Key Points
A national panel should be established to evaluate drug-drug interaction evidence and 
make recommendations as to what interactions should be included in clinical decision 
support systems.
The term “contraindicated” should be reserved for those drug pairs where co-
administration should not be permitted under any circumstances.
More research is needed to determine if filtering of drug interaction alerts can be done 
safely.
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Figure 1. 
Schematic of Transparent and Systematic Process to Develop and Maintain a Standard Set of 
DDIs for CDS Alerts
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Table 1
Examples of Mitigating Factors Allowing for Intelligent Filtering of DDI Alerts
Mitigating Factor Explanation
Drug Dose/Duration • Dose and/or duration of object or precipitant drug may be insufficient to result in an 
adverse outcome.
• A few doses of a NSAID during ACE inhibitor antihypertensive therapy are unlikely to 
result in clinically important increased blood pressure.
Timing of Administration • With some GI absorption interactions, administering the affected drug (e.g., ciprofloxacin) 
at least 2 hours before or 4-6 hours after the binding agent (e.g., ferrous sulfate) can often 
circumvent the interaction.
Route of Administration • Some routes of administration may avoid the interaction.
• With some GI absorption interactions, administering the affected drug parenterally (e.g., 
ciprofloxacin) may circumvent the interaction (e.g., with ferrous sulfate).
• Topically applied medications (e.g., erythromycin ophthalmic ointment) may not achieve 
sufficient systemic concentrations to interact.
• Caution is needed for drugs with significant absorption when administered by non-
systemic routes (e.g., inhaled fluticasone with CYP3A4 inhibitors can lead to 
hypothalamic-pituitary-adrenal axis suppression).
Sequence of Therapy • The sequence (order) of starting therapies can influence the risk of a DDI.
• When an object drug is given chronically and is carefully titrated (e.g., warfarin), adding a 
precipitant drug (e.g., amiodarone) requires careful monitoring.
• Conversely, the likelihood of a DDI is usually small when starting an object drug with 
careful titration (e.g., warfarin) for a patient already on chronic therapy with the 
precipitant drug (e.g., amiodarone).
Pharmacogenomics • Pharmacogenomics can influence the risk of a DDI.
• Patients who are genotyped to be poor metabolizers of CYP2D6 are unlikely to have a 
clinically significant interaction between venlafaxine and CYP2D6 inhibitor (e.g., 
diphenhydramine).
Indication for drug • In some cases, drugs with potentially serious DDIs may be purposely and safely co-
prescribed by experienced clinicians.
• Starting allopurinol in a patient on azathioprine can result in potentially fatal bone marrow 
suppression.
• Conversely, allopurinol and azathioprine can be beneficial for inflammatory bowel disease 
when carefully managed and monitored by a gastroenterologist.
ACE = angiotensin-converting enzyme; CYP = cytochrome P450 enzyme; DDI = drug-drug interaction GI = gastrointestinal; NSAID = 
nonsteroidal anti-inflammatory drug
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Table 2
Recommendations for Future Research to Improve DDI Alert Content
Topic Comments and Recommendations
Clinical Consequences of 
DDIs and
Frequencies
• Conduct population-based research to more clearly delineate the nature and 
frequency of DDIs and adverse outcomes associated with DDIs.
Modifying (Risk or 
Mitigating) Factors
• Identify modifying factors that are associated with lower or higher risk of harm.
Filtering Alerts • Identify methods to safely reduce repetitive and less relevant alerts.
• Demonstrate the safety of suppressing alerts at the time of renewal of previously 
tolerated medication combinations for the same patient.
• Evaluate of the impact of filtering DDI alerts based on provider type, years of 
experience, specialty, or location (e.g., unit, ward, or facility), etc.
• Determine if alerts can be safely suppressed for particular medical specialties (e.g., 
anesthesiology) or in closely managed patient care settings—such as the surgical 
suite.66
Seriousness Categories • Determine the optimal names and quantity of seriousness categories.
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